Robert W. Baird analyst Joel Beatty maintained a Buy rating on Chimerix (CMRX – Research Report) on August 3 and set a price target of $7.00. The company’s shares closed yesterday at $1.06.
Beatty covers the Healthcare sector, focusing on stocks such as Geron, Ultragenyx Pharmaceutical, and Argenx Se. According to TipRanks, Beatty has an average return of 4.7% and a 43.27% success rate on recommended stocks.
Currently, the analyst consensus on Chimerix is a Strong Buy with an average price target of $7.67, implying a 623.58% upside from current levels. In a report released on August 4, H.C. Wainwright also assigned a Buy rating to the stock with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
CMRX market cap is currently $97.44M and has a P/E ratio of 0.51.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Read More on CMRX:
- Biotech Alert: Searches spiking for these stocks today
- Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
- Chimerix reports Q2 EPS (21c), consensus (24c)
- Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
- Chimerix CEO Mike Sherman to retire, Mike Andriole to succeed
